← BASF overview

BASF vs Dow: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BASF SE (BAS.XETRA)

Q3 2026
▲2▼1

BASF's mixed Q3: asset sale, buyback, AI bet, but Rhine and EU risks

  • Coatings sale completed BASF finished selling its coatings business to Carlyle for €7.7bn, boosting cash, profit, and earnings per share while keeping a 40% stake. This strengthens the balance sheet and supports shareholder returns.

    Major completed deal that directly improved financials and cash flow.

  • AI investment and buyback BASF invested $1.1bn in AI for medical plastics and started a €1bn share buyback. These moves aim to drive future growth and return cash to shareholders, signaling confidence.

    New strategic investments and capital returns that could lift investor sentiment.

  • Rhine water and EU emissions risks Record-low Rhine water levels threaten production and raw-material supplies, while an EU emissions overhaul could raise costs. These factors create operational and regulatory uncertainty.

    Key external risks that could disrupt operations and increase expenses.

  • Evonik takeover talks BASF proposed a €12bn takeover of Evonik, which could create a European chemicals giant, but talks are early and shares fell nearly 2% on integration and funding concerns.

    Potential transformative deal with uncertain outcome and negative initial market reaction.

August 2026
▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

  • Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.

    This is the period's biggest positive fundamental news and directly supports the share price.

  • Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.

    It shows a broad industry pricing upturn that directly benefits BASF's earnings.

  • Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.

    This is a real operational risk that could hurt earnings and weigh on the stock.

  • Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.

    This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

Latest
▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

  • Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.

    This is the period's biggest positive fundamental news and directly supports the share price.

  • Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.

    It shows a broad industry pricing upturn that directly benefits BASF's earnings.

  • Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.

    This is a real operational risk that could hurt earnings and weigh on the stock.

  • Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.

    This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

July 2026
▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

  • Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.

    This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.

  • New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.

    A concrete new product launch that supports future revenue growth in a profitable segment.

  • AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.

    Shows BASF investing in technology that may improve margins and competitiveness over time.

  • EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.

    A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.

▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

  • Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.

    This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.

  • New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.

    A concrete new product launch that supports future revenue growth in a profitable segment.

  • AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.

    Shows BASF investing in technology that may improve margins and competitiveness over time.

  • EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.

    A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.

Dow Inc (DOW)

Q3 2026
▼2

Dow cuts outlook, faces Canada tariffs, weighs Sadara sale

  • Canada tariffs hit Dow exports Canada's retaliatory tariffs on U.S. goods took effect September 8, hitting plastics and chemicals that include Dow products. This makes Dow's exports to Canada more expensive, likely reducing sales and pressuring profit.

    New trade barrier directly affecting Dow's sales and pricing power.

  • Dow weighs selling Sadara stake Dow is reportedly considering selling its 35% stake in the $20 billion Sadara joint venture with Saudi Aramco. A sale could bring cash but forfeit future recovery upside, and the headline $20 billion is not the current value of Dow's stake.

    Portfolio move with major cash and strategic implications for Dow's balance sheet.

  • Dow trims Q3 EBITDA outlook Dow cut its third-quarter EBITDA forecast to $1.5–1.6 billion, citing weaker polyethylene pricing in the Americas and soft construction and automotive demand. This signals near-term earnings pressure, though cost cuts and working-capital release offer some offset.

    Direct reduction in expected earnings, a key driver of stock value.

  • Debt paydown prioritized over buybacks Dow will use excess cash to reduce debt and does not expect share buybacks in 2026, keeping the $0.35 dividend as the main shareholder return. This strengthens the balance sheet but removes a potential stock support, and the dividend is half its former level.

    Capital allocation shift affects shareholder returns and financial risk.

August 2026
▼2

Dow cuts outlook, faces Canada tariffs, weighs Sadara sale

  • Canada tariffs hit Dow exports Canada's retaliatory tariffs on U.S. goods took effect September 8, hitting plastics and chemicals that include Dow products. This makes Dow's exports to Canada more expensive, likely reducing sales and pressuring profit.

    New trade barrier directly affecting Dow's sales and pricing power.

  • Dow weighs selling Sadara stake Dow is reportedly considering selling its 35% stake in the $20 billion Sadara joint venture with Saudi Aramco. A sale could bring cash but forfeit future recovery upside, and the headline $20 billion is not the current value of Dow's stake.

    Portfolio move with major cash and strategic implications for Dow's balance sheet.

  • Dow trims Q3 EBITDA outlook Dow cut its third-quarter EBITDA forecast to $1.5–1.6 billion, citing weaker polyethylene pricing in the Americas and soft construction and automotive demand. This signals near-term earnings pressure, though cost cuts and working-capital release offer some offset.

    Direct reduction in expected earnings, a key driver of stock value.

  • Debt paydown prioritized over buybacks Dow will use excess cash to reduce debt and does not expect share buybacks in 2026, keeping the $0.35 dividend as the main shareholder return. This strengthens the balance sheet but removes a potential stock support, and the dividend is half its former level.

    Capital allocation shift affects shareholder returns and financial risk.

Latest
▼2

Dow cuts outlook, faces Canada tariffs, weighs Sadara sale

  • Canada tariffs hit Dow exports Canada's retaliatory tariffs on U.S. goods took effect September 8, hitting plastics and chemicals that include Dow products. This makes Dow's exports to Canada more expensive, likely reducing sales and pressuring profit.

    New trade barrier directly affecting Dow's sales and pricing power.

  • Dow weighs selling Sadara stake Dow is reportedly considering selling its 35% stake in the $20 billion Sadara joint venture with Saudi Aramco. A sale could bring cash but forfeit future recovery upside, and the headline $20 billion is not the current value of Dow's stake.

    Portfolio move with major cash and strategic implications for Dow's balance sheet.

  • Dow trims Q3 EBITDA outlook Dow cut its third-quarter EBITDA forecast to $1.5–1.6 billion, citing weaker polyethylene pricing in the Americas and soft construction and automotive demand. This signals near-term earnings pressure, though cost cuts and working-capital release offer some offset.

    Direct reduction in expected earnings, a key driver of stock value.

  • Debt paydown prioritized over buybacks Dow will use excess cash to reduce debt and does not expect share buybacks in 2026, keeping the $0.35 dividend as the main shareholder return. This strengthens the balance sheet but removes a potential stock support, and the dividend is half its former level.

    Capital allocation shift affects shareholder returns and financial risk.

Q2 2026
▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

June 2026
▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

© 2026 MarketIVWhy